Melatonin therapy was also seen to improve sleep quality, cognitive performance, memory, and depression in patients with mild cognitive impairment. Although melatonin therapy does not appear to be a potential cure for Alzheimer disease it does provide some important
neurologic benefits in the appropriate patient population. AD is characterized by the progressive loss of cognitive functions and memory, but can also be accompanied by neurobehavioral manifestations. Mild cognitive impairment (MCI) is thought to be the intermediate stage between expected cognitive decline of normal aging and the more pronounced decline seen in dementia. According to the 2011 updates guidelines for AD, the symptomatic predementia phase of AD is now referred to as MCI due to AD. The second section focuses on clinical trials involving melatonin therapy in patient populations diagnosed with AD and MCI. The searches were specific to the keywords âmelatoninâ, âAlzheimer diseaseâ, and âmild cognitive impairmentâ. The results were limited to publications no older than January 2010. There have been several studies and reviewsperformed on evaluating the effectiveness of melatonin in AD patients with sleep disorders and in patients with mild cognitive impairment.
John K. Grandy, Melatonin: Therapeutic Intervention in Mild Cognitive Impairment and
Last date updated on June, 2014